Suppr超能文献

靶向拓扑异构酶I的小分子抑制剂作为新型抗结核药物

Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.

作者信息

Sandhaus Shayna, Annamalai Thirunavukkarasu, Welmaker Greg, Houghten Richard A, Paz Carlos, Garcia Pamela K, Andres Angelo, Narula Gagandeep, Rodrigues Felix Carolina, Geden Sandra, Netherton Mandy, Gupta Rashmi, Rohde Kyle H, Giulianotti Marc A, Tse-Dinh Yuk-Ching

机构信息

Department of Chemistry and Biochemistry, Florida International University, Miami, Florida, USA.

Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida, USA.

出版信息

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4028-36. doi: 10.1128/AAC.00288-16. Print 2016 Jul.

Abstract

Bacterial topoisomerase functions are required for regulation of DNA supercoiling and overcoming the DNA topological barriers that are encountered during many vital cellular processes. DNA gyrase and topoisomerase IV of the type IIA bacterial topoisomerase family are important clinical targets for antibacterial therapy. Topoisomerase I, belonging to the type IA topoisomerase family, has recently been validated as a potential antitubercular target. The topoisomerase I activity has been shown to be essential for bacterial viability and infection in a murine model of tuberculosis. Mixture-based combinatorial libraries were screened in this study to identify novel bacterial topoisomerase I inhibitors. Using positional-scanning deconvolution, selective small-molecule inhibitors of bacterial topoisomerase I were identified starting from a polyamine scaffold. Antibacterial assays demonstrated that four of these small-molecule inhibitors of bacterial topoisomerase I are bactericidal against Mycobacterium smegmatis and Mycobacterium tuberculosis The MICs for growth inhibition of M. smegmatis increased with overexpression of recombinant M. tuberculosis topoisomerase I, consistent with inhibition of intracellular topoisomerase I activity being involved in the antimycobacterial mode of action.

摘要

细菌拓扑异构酶功能对于调节DNA超螺旋以及克服许多重要细胞过程中遇到的DNA拓扑障碍是必需的。IIA型细菌拓扑异构酶家族的DNA促旋酶和拓扑异构酶IV是抗菌治疗的重要临床靶点。属于IA型拓扑异构酶家族的拓扑异构酶I最近已被确认为潜在的抗结核靶点。在结核病小鼠模型中,拓扑异构酶I活性已被证明对细菌生存能力和感染至关重要。在本研究中对基于混合物的组合文库进行了筛选,以鉴定新型细菌拓扑异构酶I抑制剂。使用位置扫描去卷积法,从多胺支架出发鉴定出了细菌拓扑异构酶I的选择性小分子抑制剂。抗菌试验表明,这些细菌拓扑异构酶I的小分子抑制剂中有四种对耻垢分枝杆菌和结核分枝杆菌具有杀菌作用。随着重组结核分枝杆菌拓扑异构酶I的过表达,耻垢分枝杆菌生长抑制的最低抑菌浓度增加,这与抑制细胞内拓扑异构酶I活性参与抗分枝杆菌作用模式一致。

相似文献

3
DNA topoisomerase I and DNA gyrase as targets for TB therapy.DNA拓扑异构酶I和DNA回旋酶作为结核病治疗的靶点。
Drug Discov Today. 2017 Mar;22(3):510-518. doi: 10.1016/j.drudis.2016.11.006. Epub 2016 Nov 14.
4

引用本文的文献

1
: Pathogenesis and therapeutic targets.发病机制与治疗靶点。
MedComm (2020). 2023 Sep 4;4(5):e353. doi: 10.1002/mco2.353. eCollection 2023 Oct.
6
"Upcycling" known molecules and targets for drug-resistant TB.将已知的耐药结核病药物分子和靶点进行“升级利用”。
Front Cell Infect Microbiol. 2022 Oct 6;12:1029044. doi: 10.3389/fcimb.2022.1029044. eCollection 2022.
7
Small DNA circles as bacterial topoisomerase I inhibitors.作为细菌拓扑异构酶I抑制剂的小DNA环。
RSC Adv. 2019 Jun 11;9(32):18415-18419. doi: 10.1039/c9ra02398d. eCollection 2019 Jun 10.
9
Direct observation of topoisomerase IA gate dynamics.直接观察拓扑异构酶 IA 门控动力学。
Nat Struct Mol Biol. 2018 Dec;25(12):1111-1118. doi: 10.1038/s41594-018-0158-x. Epub 2018 Nov 26.

本文引用的文献

1
The negative impact of antibiotic resistance.抗生素耐药性的负面影响。
Clin Microbiol Infect. 2016 May;22(5):416-22. doi: 10.1016/j.cmi.2015.12.002. Epub 2015 Dec 17.
8
Extensively drug-resistant tuberculosis: epidemiology and management.广泛耐药结核病:流行病学与管理
Clin Epidemiol. 2014 Apr 1;6:111-8. doi: 10.2147/CLEP.S35839. eCollection 2014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验